Hi Disaster,
From the report you shared.
“The investigators concluded that approximately one-third of patients undergoing TAVR failed to improve their exercise capacity after the procedure. The lack of functional improvement after TAVR was predicted by a mix of baseline and periprocedural factors translating into poorer clinical outcomes.”
Plus, this is a 6 month report and after that typically patients get worse not better. Ours improved a further 17% from 30 days to 12 months! Not to mention that some of our patients were older and actually on their death bed. One patient had 2 to 3 weeks to live and now has normal valve function. Amazing.
I think this is keeping it real.
Ann: DurAVR First in Human Study 12 Month Results, page-16
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.15 |
Change
-0.500(3.19%) |
Mkt cap ! $291.2M | |||
| Open | High | Low | Value | Volume |
| $15.75 | $15.75 | $15.00 | $294.3K | 19.33K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1135 | $15.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.35 | 88 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |